Abstract:BACKGROUND Antibody-mediated rejection following liver transplantation (LT) has been increasingly recognized, particularly with respect to the emergence of de novo donor-specific antibodies (DSAs) and their impact on graft longevity. While substantial evidence for adult populations exists, research focusing on pediatric LT outcomes remains limited. AIM To investigate the prevalence of human leukocyte antigen (HLA) mismatches and DSA and evaluate their association with rejection episodes after pediatric LT. METHODS A cohort of pediatric LT recipients underwent HLA testing at Santa Casa de Porto Alegre, Brazil, between December 2013 and December 2023. Only patients who survived for > 30 days after LT with at least one DSA analysis were included. DSA classes I and II and cross-matches were analyzed. The presence of de novo DSA (dnDSA) was evaluated at least 3 months after LT using the Luminex® single antigen bead method, with a positive reaction threshold set at 1000 MFI. Rejection episodes were confirmed by liver biopsy. RESULTS Overall, 67 transplanted children were analyzed; 61 received grafts from living donors, 85% of whom were related to recipients. Pre-transplant DSA (class I or II) was detected in 28.3% of patients, and dnDSA was detected in 48.4%. The median time to DSA detection after LT was 19.7 [interquartile range (IQR): 4.3-35.6] months. Biopsy-proven rejection occurred in 13 patients at follow-up, with C4d positivity observed in 5/13 Liver biopsies. The median time to rejection was 7.8 (IQR: 5.7-12.8) months. The presence of dnDSA was significantly associated with rejection (36% vs 3%, P < 0.001). The rejection-free survival rates at 12 and 24 months were 76% vs 100% and 58% vs 95% for patients with dnDSA anti-DQ vs those without, respectively. CONCLUSION Our findings highlight the importance of incorporating DSA assessment into pre- and post-transplantation protocols for pediatric LT recipients. Future implications may include immunosuppression minimization strategies based on this analysis in pediatric LT recipients.

Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation

Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation

Comparative outcomes of DSA positive, crossmatch negative living donor kidney transplants versus remaining on the waitlist for an HLA compatible deceased donor

Differences in chronic lung allograft dysfunction between deceased-donor lung transplantation and living-donor lobar lung transplantation

Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations

Long-term Clinical Relevance of De Novo Donor-Specific Antibodies after Pediatric Liver Transplantation.

Post-transplant donor-specific anti-HLA antibodies with a higher mean fluorescence intensity are associated with graft fibrosis in pediatric living donor liver transplantation

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

Local intragraft humoral immune responses in chronic lung allograft dysfunction

Impact of Preformed Donor-specific Antibodies in Comparison to ABO Incompatibility in Living Donor Liver Transplantation: A Propensity Score–Matched Analysis

Understanding the Significance of Low-Level Preformed Donor-Specific Anti-Hla Antibodies in Renal Transplant Patients.

Chronological alterations in de novo malignancies after living‐donor liver transplantation: A cohort study of 1781 recipients using annual comparisons of standardized incidence ratios

Association between Respiratory Virus Infection and Development of De Novo Donor-Specific Antibody in Lung Transplant Recipients

De Novo DSA in the Setting of Stable Renal Allograft Function is a Benign Finding

Influence of de novo donor-specific antibody on early renal allograft function recovery.

Comparison of Graft Outcome Between Donation After Circulatory Death and Living-Donor Kidney Transplantation.

Roles and practice of living-related lobar lung transplantation

The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series

The natural history of de novo donor-specific HLA antibodies after kidney transplantation

Human leukocyte antigen compatibility and incidence of donor-specific antibodies in pediatric liver transplant recipients

Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation